<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04958265</url>
  </required_header>
  <id_info>
    <org_study_id>BO42354</org_study_id>
    <secondary_id>2020-002437-15</secondary_id>
    <nct_id>NCT04958265</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)</brief_title>
  <acronym>COMMUTE-p</acronym>
  <official_title>A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants&#xD;
      with aHUS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2021</start_date>
  <completion_date type="Anticipated">March 16, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with complete TMA response (cTMAr) (Naive Cohort only)</measure>
    <time_frame>Baseline up to Week 25</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dialysis Requirement Status (Yes/No) (Naive and Switch Cohorts)</measure>
    <time_frame>Baseline up to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Value in Estimated Glomerular Filtration Rate (eGFR) (Naive and Switch Cohorts)</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated Glomerular Filtration Rate (eGFR) (Naive and Switch Cohorts)</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Change from Baseline in Chronic Kidney Disease (CKD) stage (Naive and Switch Cohorts)</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Value in Platelet Count (Naive and Switch Cohorts)</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Value in Lactate Dehydrogenase (LDH) (mg/dL) (Naive and Switch Cohorts)</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed Value in Hemoglobin (mg/dL) (Naive and Switch Cohorts)</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Platelet Count (Naive and Switch Cohorts)</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Lactate Dehydrogenase (LDH) (mg/dL) (Naive and Switch Cohorts)</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Hemoglobin (mg/dL) (Naive and Switch Cohorts)</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Platelet Count &gt;= LLN (Naive Cohort only)</measure>
    <time_frame>Baseline up to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Normalisation of LDH (i.e., =&lt; ULN) (Naive Cohort only)</measure>
    <time_frame>Baseline up to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with &gt;=25% decrease in Serum Creatinine (Naive Cohort only)</measure>
    <time_frame>Baseline up to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete TMA response (cTMAr) (Naive Cohort only)</measure>
    <time_frame>Baseline up to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete TMA response (cTMAr) (Naive Cohort only)</measure>
    <time_frame>Baseline up to Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with complete TMA response (cTMAr) (Naive Cohort only)</measure>
    <time_frame>Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with maintained TMA control (mTMAc) (Switch Cohort only)</measure>
    <time_frame>Baseline through Week 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Injection-Site Reactions, Infusion-Related Reactions, Hypersensitivity, Malignant Hypertension (including malignant renal hypertension) and Infections (including meningococcal meningitis)</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs) leading to Study Drug Discontinuation</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with clinical manifestations of Drug-Target-Drug Complex (DTDC) formation amongst participants who switched to crovalimab treatment from eculizumab/ravulizumab treatment (Switch Cohort and switching Pretreated participants)</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentrations of Crovalimab over time</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-Crovalimab Antibodies</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Atypical Hemolytic Uremic Syndrome</condition>
  <arm_group>
    <arm_group_label>Crovalimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be enrolled in three cohorts: [1] Naive Cohort - participants who have not been previously treated with complement inhibitor therapy; [2] Switch Cohort - participants who switch to crovalimab from another C5 inhibitor and [3] Pretreated Cohort (includes C5 SNP (Single Nucleotide Polymorphism) participants) - participants who received treatment with another C5 inhibitor and subsequently discontinued it.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crovalimab</intervention_name>
    <description>Crovalimab will be administered at a dose of 1000 mg intravenously (IV) (for participants weighing 40 to &lt;100 kg) or 1500 mg IV (for participants weighing &gt;=100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, crovalimab will be administered at a dose of 340 mg subcutaneously (SC). On Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants weighing 40 to &lt;100 kg) or 1020 mg SC (for participants weighing &gt;=100 kg). Enrollment of participants weighing &lt;40 kg will be staggered using two weight-based dose confirmation groups (Group 1 participants weighing &gt;=20 kg to &lt;40 kg, followed by Group 2 participants weighing &gt;=5 kg to &lt;20 kg). All participants will receive an initial IV loading dose, which will be followed by SC dosing at either Q2W or Q4W intervals (depending on body weight), until study completion.</description>
    <arm_group_label>Crovalimab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight &gt;= 5 kg at screening.&#xD;
&#xD;
          -  Vaccination against Neisseria meningitidis.&#xD;
&#xD;
          -  For participants receiving other therapies (e.g., immunosuppressants, corticosteroids,&#xD;
             mTORi, or calcineurin inhibitors: stable dose for &gt;= 28 days.&#xD;
&#xD;
          -  For female participants of childbearing potential: an agreement to remain abstinent or&#xD;
             use contraception.&#xD;
&#xD;
          -  Participants with a prior kidney transplant are eligible if they have a known history&#xD;
             of complement-mediated aHUS prior to the kidney transplant.&#xD;
&#xD;
          -  Evidence of TMA (for Naive Cohort only).&#xD;
&#xD;
          -  Onset of TMA =&lt;28 days prior to first crovalimab administration (for Naive Cohort and&#xD;
             participants in the Pretreated Cohort with TMA present at the time of screening).&#xD;
&#xD;
          -  Documented treatment with a C5 inhibitor (for Switch Cohort only).&#xD;
&#xD;
          -  Clinical evidence of response to a C5 inhibitor (for Switch Cohort only).&#xD;
&#xD;
          -  Poorly controlled TMA following treatment with another C5 inhibitor (for C5 SNP&#xD;
             participants in the Pretreated Cohort only).&#xD;
&#xD;
          -  Known C5 polymorphism (for C5 SNP participants in the Pretreated Cohort only).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  TMA associated with non-aHUS related renal disease.&#xD;
&#xD;
          -  Positive direct Coombs test.&#xD;
&#xD;
          -  Chronic dialysis and/or end stage renal disease.&#xD;
&#xD;
          -  Identified drug exposure-related TMA.&#xD;
&#xD;
          -  Presence or history of a condition that could trigger TMA, such as malignancy, organ&#xD;
             transplant (other than kidney transplant) or autoimmune disease.&#xD;
&#xD;
          -  History of a kidney disease, other than aHUS.&#xD;
&#xD;
          -  History of Neisseria meningitidis infection within 6 months.&#xD;
&#xD;
          -  Known or suspected immune deficiency (e.g., history of frequent recurrent infections).&#xD;
&#xD;
          -  Positive HIV test.&#xD;
&#xD;
          -  Multi-system organ dysfunction or failure.&#xD;
&#xD;
          -  Recent IVIg treatment.&#xD;
&#xD;
          -  Pregnant or breastfeeding or intending to become pregnant.&#xD;
&#xD;
          -  Participation in another interventional treatment study with an investigational agent&#xD;
             or use of any experimental therapy within 28 days of screening or within five half&#xD;
             lives of that investigational product, whichever is greater.&#xD;
&#xD;
          -  Recent use of tranexamic acid.&#xD;
&#xD;
          -  Current or previous treatment with a complement inhibitor (for Naive Cohort only).&#xD;
&#xD;
          -  Positive for Active Hepatitis B and/or C infections (HBV/HCV) (for Switch Cohort and&#xD;
             switching C5 SNP Pretreated Cohort participants who recently received C5 inhibitor&#xD;
             treatment).&#xD;
&#xD;
          -  Cryoglobulinemia at screening (for Switch Cohort and C5 SNP Cohort participants who&#xD;
             recently received C5 inhibitor treatment).&#xD;
&#xD;
          -  Documented condition leading to non-aHUS TMA: Thrombotic Thrombocytopenic Purpura&#xD;
             (TTP), Shiga Toxin producing Escherichia Coli (STEC)-TMA, Pneumococcal HUS, TMA&#xD;
             secondary to cobalamin C defect and TMA related to Diacylglycerol kinase Îµ (DGKE)&#xD;
             nephropathy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BO42354 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>China</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azotemia</mesh_term>
    <mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
    <mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

